All regulatory updates
718 results found
ECHA updates Registry of SVHC intentions until outcome (pipeline tracker)
ECHA’s Registry of SVHC intentions until outcome (the official pipeline/status tracker for planned SVHC identification work) is indicated in the research as updated on 4 February 2026. This does not itself add substances to the Candidate List, but it is a compliance-relevant tracking update because it signals potential upcoming SVHC identifications that could later trigger Article 33 communication and related downstream duties once substances are included on the Candidate List.
ECHA Candidate List table shows n-hexane included as SVHC (date of inclusion: 4 February 2026) with Article 57(f) basis
ECHA’s official REACH Candidate List table shows n-hexane included on the Candidate List with date of inclusion 04-Feb-2026. The listing indicates the SVHC identification basis under REACH Article 57(f) (equivalent level of concern) related to human health (specific target organ toxicity after repeated exposure). This triggers downstream REACH SVHC compliance duties (e.g., Article 33 communication for articles containing the SVHC above 0.1% w/w and related supply-chain information management).
ECHA Registry of SVHC intentions until outcome updated (pipeline/status tracker)
ECHA updated its official "Registry of SVHC intentions until outcome" (page shows last updated 04 Feb 2026). While not a Candidate List change itself, this is an official process/status tracking update used by compliance teams to monitor forthcoming SVHC identification dossiers and their progression through the REACH Article 59 process.
ECHA updates Registry of SVHC intentions until outcome (page shows last updated 4 February 2026)
ECHA’s Registry of SVHC intentions until outcome indicates it was last updated on 4 February 2026. This is a process-tracking update (pipeline visibility) rather than a Candidate List inclusion itself, but it is relevant for compliance monitoring because it signals potential upcoming SVHC identification dossiers that may later drive Candidate List additions (and downstream Article 33/SCIP and Article 7(2) notification impacts if substances are eventually listed).
ECHA updates Registry of SVHC intentions until outcome (last updated 4 Feb 2026)
ECHA refreshed the ‘Registry of SVHC intentions until outcome’ (page shows “Last updated 04 February 2026”), reflecting the current status of SVHC identification intentions and outcomes (e.g., entries marked as withdrawn/identified). While not a Candidate List inclusion itself, this update is directly relevant to REACH SVHC monitoring because it signals changes in the SVHC identification pipeline that compliance teams track for upcoming Candidate List proposals and consultations.
U.S. Department of State release on 2026 Critical Minerals Ministerial references NOFO for a Rare Earth Elements Demonstration Facility
The U.S. Department of State published a release on the 2026 Critical Minerals Ministerial that references U.S. funding initiatives tied to critical minerals, including a Notice of Funding Opportunity (NOFO) to establish a Rare Earth Elements (REE) Demonstration Facility (referenced as dated Dec. 1, 2025 within the release). While programmatic rather than a binding regulation, it can affect compliance-relevant expectations for project eligibility, supply-chain due diligence, and procurement requirements for organizations seeking to participate in U.S.-supported REE initiatives.
Illinois SB3323 introduced to exclude specified drugs from the PMP and require purging testosterone PMP records by Jan 1, 2027
Illinois SB3323 (104th General Assembly) was introduced to amend 720 ILCS 570/316 and add new 720 ILCS 570/316.2. As described in the research text, the bill would provide that the Illinois Prescription Monitoring Program does not apply to specified drugs (testosterone, mifepristone, misoprostol, GnRH analogues, estrogen). It would also require the Illinois Department of Human Services to purge existing PMP records concerning testosterone by January 1, 2027 and adopt/update implementing rules by January 1, 2027. Compliance impact: could change PMP reporting/recordkeeping scope for dispensers and PMP system operators, and require data retention/deletion processes tied to testosterone records.
Illinois HB4602 introduced to condition interstate Prescription Monitoring Program (PMP) data sharing on mutual reciprocity
Illinois HB4602 (104th General Assembly) was introduced to amend 720 ILCS 570/316.1 regarding Prescription Monitoring Program (PMP) integration and interstate data sharing. As described in the research text, the bill would require interstate PMP data-sharing agreements to be “mutual” (i.e., Illinois would only share PMP data if the reciprocal state provides Illinois-licensed healthcare entities and application vendors an opportunity to access that state’s PMP data). Compliance impact: could affect cross-border PMP query workflows, interoperability arrangements, and contracts/technical integrations used by prescribers, dispensers, and PMP/EHR integration vendors.
Commission Regulation (EU) 2026/250 corrects BPA food contact materials restriction and transitional provisions in Regulation (EU) 2024/3190
Commission Regulation (EU) 2026/250 (published in the Official Journal on 3 Feb 2026) corrects errors/inconsistencies in Regulation (EU) 2024/3190 restricting BPA and certain bisphenols in specific food contact materials (adopted under Regulation (EC) No 1935/2004). The corrigendum clarifies scope/prohibition wording (including ‘placing on the Union market’) and replaces/corrects transitional provisions for certain single-use final food contact articles. Key clarified timelines include: (i) certain single-use final articles manufactured using BPA under prior rules may be first placed on the market until 20 July 2026; (ii) certain specified packaging/articles may be first placed on the market until 20 January 2028; and (iii) corrected ‘remain on the market’ dates for certain repeat-use articles (until 20 July 2027 or 20 January 2029 depending on the transitional pathway). Compliance teams should reassess product eligibility under the corrected transitional wording and update market placement/stock management plans and documentation wording accordingly.
Commission Regulation (EU) 2026/245 amends Annex I (Union List) of Regulation (EU) No 10/2011 for plastic food contact materials
Commission Regulation (EU) 2026/245 (published in the Official Journal on 3 Feb 2026) amends Annex I (the Union List) to Regulation (EU) No 10/2011 on plastic materials and articles intended to come into contact with food (an implementing measure under Regulation (EC) No 1935/2004). The amendment updates authorisations and/or conditions of use for multiple listed substances used in plastic FCMs, including introducing or revising specific migration limits (SMLs) and other restrictions (e.g., limitations by food type such as exclusions for infant formula/human milk contact; notes on compliance verification). Compliance teams should review the updated Union List entries for impacted additives/starting substances, verify that formulations and intended uses meet revised conditions (including SML and use restrictions), and update declarations of compliance and supporting testing/verification plans as needed.
Commission Regulation (EU) 2026/245 amends Annex I (Union list) of Plastics FCM Regulation (EU) No 10/2011 (authorisations/conditions of use)
The European Commission adopted Commission Regulation (EU) 2026/245 (2 February 2026) amending Annex I (the Union list of authorised substances) of Regulation (EU) No 10/2011 on plastic materials and articles intended to come into contact with food. Updates to Annex I can change substance authorisations and/or conditions of use for plastic FCMs, directly impacting substance compliance status, supporting evidence files, and declarations of compliance under the EU FCM Framework Regulation (EC) No 1935/2004.
Illinois SB3191 introduced to increase fentanyl-related penalties (Class X felony for selling/dispensing fentanyl-containing scheduled drugs; added penalty for use of electronic communication device in trafficking)
SB3191 (104th General Assembly) was introduced on 2026-02-02 and proposes amendments to the Illinois Controlled Substances Act (including 720 ILCS 570/401 and 720 ILCS 570/401.1) to increase/modify fentanyl-related criminal penalties. As summarized in the introduced bill text, it would make unlawfully selling or dispensing any scheduled drug containing a detectable amount of fentanyl a Class X felony with specified sentencing/fine provisions, and would add a felony provision for knowingly using an electronic communication device in furtherance of controlled substance trafficking involving any amount of fentanyl (in addition to other penalties). Compliance and risk teams in healthcare/pharmacy and regulated distribution should monitor because changes could affect enforcement risk, diversion prevention programs, and reporting/escalation practices around suspected fentanyl diversion or illicit distribution.
ECHA launched public consultation for the 13th draft recommendation to include SVHCs in Annex XIV (Authorisation List)
ECHA opened a public consultation on its 13th draft recommendation for prioritising SVHCs for inclusion in REACH Annex XIV (Authorisation List). The recommendation status is shown as 'included in draft recommendation' with a consultation window from 02-Feb-2026 to 02-May-2026. While this is not yet a binding Annex XIV amendment, it is a key step toward future authorisation requirements (e.g., eventual latest application and sunset dates) for substances selected by the European Commission. Compliance teams should review whether any listed substances are used in their products/processes and consider submitting comments during the consultation period and preparing for potential downstream authorisation impacts if the Commission proceeds.
CDC/NIOSH Request for Information (RFI) opens public comment on NIOSH Center for Firefighter Safety, Health and Well-Being portfolio (Docket CDC-2026-0133; NIOSH-356)
CDC/NIOSH published a Federal Register Request for Information seeking stakeholder input on priorities for the NIOSH Center for Firefighter Safety, Health and Well-Being portfolio. The notice states it does not propose new regulations or requirements, but it is a formal, docketed action that can influence future NIOSH research, program priorities, and potential downstream guidance affecting firefighter safety and health programs. Comments are due April 3, 2026 via the specified docket.
Illinois SB3191 introduced and referred to Senate Assignments; would increase fentanyl-related penalties and add offense for using an electronic communication device in fentanyl trafficking
SB3191 is proposed legislation to amend the Illinois Controlled Substances Act provisions (including 720 ILCS 570/401 and 720 ILCS 570/401.1) by increasing penalties for certain fentanyl-related conduct. As described in the bill materials, it would make unlawfully selling/dispensing any scheduled drug containing a detectable amount of fentanyl a Class X felony (with specified imprisonment range and fines), and it would add a separate Class 1 felony for knowingly using an electronic communication device in furtherance of controlled substance trafficking involving fentanyl. The ILGA bill status shows the bill was referred to Senate Assignments on 2/02/2026. Compliance teams should monitor for enactment and prepare for potential updates to controlled-substance compliance programs, training, and risk assessments tied to fentanyl-containing products and communications evidence.
Illinois SB3221 referred to Senate Assignments; bill proposes adding xylazine as a Class III controlled substance with exemptions (effective date in bill: Jan 1, 2027)
SB3221 is pending legislation that would amend the Illinois Controlled Substances Act by adding xylazine as a Class III controlled substance and making related structural changes to controlled substance lists/definitions, while carving out specified exemptions (e.g., certain veterinary/animal-drug and professional use contexts). The ILGA bill status reflects a latest action of referral to Senate Assignments (2/02/2026). The synopsis indicates a proposed effective date of January 1, 2027. Compliance teams should monitor whether xylazine becomes scheduled in Illinois, evaluate supply chain and dispensing controls, and review applicability of any exemptions for veterinary and other permitted uses.
SB3221 introduced to add xylazine as a Schedule III controlled substance and reorganize controlled substance schedules (effective date proposed)
Illinois SB3221 (104th GA) proposes amendments to the Illinois Controlled Substances Act to make structural/organizational changes to controlled substance schedules and to add xylazine as a Schedule III controlled substance, with specified exceptions per the bill synopsis. The bill status/synopsis indicates a proposed effective date of January 1, 2027. Compliance relevance: if enacted, xylazine scheduling would trigger controlled substance handling, security, and compliance screening requirements for impacted entities (including veterinary-related stakeholders depending on exemptions).
European Commission DG SANTE publishes SCoPAFF Working Group handout on implementation of recycled plastics FCM rules (Reg. (EU) 2022/1616)
European Commission (DG SANTE) published a handout for the Working Group of the Standing Committee on Plants, Animals, Food and Feed (SCoPAFF) on Food Contact Materials (meeting 29–30 January 2026). The document provides implementation-status updates and practical clarifications relevant to compliance with the recycled plastic food contact materials regime under Regulation (EU) 2022/1616, which is a specific measure adopted under the EU Food Contact Materials Framework Regulation (EC) No 1935/2004. Topics include the Recycling Register/IT system rollout (FFSPM/FIP and planned ESFC tool structuring), Member State audits/controls under Article 26 of Regulation (EU) 2022/1616, status of PET recycling authorisation decisions, and discussion of recent corrections to Regulation (EU) 2022/1616 (Commission Regulation (EU) 2025/2269). Compliance teams using recycled plastics should monitor the operational timelines and documentation/registration expectations described, as these affect market access and audit readiness.
Commission Regulation (EU) 2026/250 corrects the BPA/bisphenols FCM rules in Regulation (EU) 2024/3190 (incl. transitional provisions)
The European Commission adopted Commission Regulation (EU) 2026/250 (2 February 2026) as a correcting act (corrigendum) to Commission Regulation (EU) 2024/3190 on the use of bisphenol A (BPA) and other bisphenols and bisphenol derivatives in certain food contact materials. The Commission’s Food Contact Materials legislation index flags the correction as particularly relevant to transitional provisions, which may affect sell-through, declarations of compliance, and compliance planning for operators placing affected FCMs on the EU market under the Framework Regulation (EC) No 1935/2004.
SB3213 introduced to expand/clarify e-prescribing exceptions and align controlled-substance prescription transfer limits
Illinois SB3213 (introduced; not shown as enacted in provided materials) would amend 720 ILCS 570/311.6 to add/clarify exceptions to the requirement that Schedule II–V controlled substance prescriptions be issued electronically, including circumstances such as after-hours access needs and drug shortages/inventory limitations. The bill also proposes changes (in the Pharmacy Practice Act) to align controlled-substance prescription transfer rules with federal requirements (e.g., one-time transfer with an exception for shared real-time databases). Compliance teams for prescribers and pharmacies should monitor for potential workflow and policy changes on when paper/alternative prescribing is permitted and how transfers are handled.